Borderline personality disorder
Drug research and approvals for borderline personality disorder: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 42 studies of borderline personality disorder are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 42
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Efficacy and Mechanisms of Change of Two Brief Treatments for Borderline Personality DisorderNCT07940660 · Not applicable · University of Lausanne Hospitals · starts Oct 1, 2026
- Repetitive Transcranial Magnetic Stimulation Versus Theta Burst Stimulation on Impulsivity, Emotional Dysregulation,…NCT07919587 · Not applicable · Ain Shams University · starts Dec 1, 2025
- Effectiveness of Enhanced Dialectical Behavior Therapy Skills Training Group for Borderline Personality DisorderNCT07875166 · Not applicable · Hospital Dr Sotero del Rio · starts Jun 18, 2025
- Symptom Assessment in Adolescents Placed on Child WelfareNCT07794332 · Not reported · University Hospital, Strasbourg, France · starts Jan 30, 2026
- Combining Transcranial Magnetic Stimulation With Emotion Regulation Skills Training in Borderline Personality DisorderNCT07714005 · Not applicable · Massachusetts General Hospital · starts Sep 1, 2026
- The Role of Gender in Borderline Personality DisorderNCT07639957 · Not reported · University Hospital Heidelberg · starts May 29, 2026
- Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression…NCT07569198 · Phase 2 · Joshua Rosenblat · starts Jul 16, 2026
- Oxytocin Plus Self-compassion Training in Borderline Personality DisorderNCT07551882 · Phase 2 · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · starts Jan 10, 2024
- ADOLESCENTS IMAGING USING fMRI: Feasibility StudyNCT07540429 · Not applicable · Etablissement Public de la Sante Mentale de la Somme · starts Jun 8, 2024
Phase 3 4
- OlanzapineSerotonin 2a (5-HT2a) receptor antagonist
- QuetiapineSerotonin 2a (5-HT2a) receptor antagonist
- NaltrexoneOpioid receptors; mu/kappa/delta antagonist
- SelegilineMonoamine oxidase B inhibitor
Phase 2 12
- BrexpiprazoleDopamine D2 receptor partial agonist
- AcetaminophenCyclooxygenase inhibitor
- EscitalopramSerotonin transporter inhibitor
- IncobotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- MifepristoneGlucocorticoid receptor antagonist
- ZiprasidoneSerotonin 2a (5-HT2a) receptor antagonist
- LumateperoneSerotonin 2a (5-HT2a) receptor antagonist
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
- Amylase (pancrelipase)Starch hydrolytic enzyme
- N-methyl-d-aspartic acid (nmda)
- Vafidemstat
How its trials ended
241 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 41 whose ending is known, 41% met their primary endpoint, 15% missed it and 44% stopped early.
- Completed, result not reported9640%
- Ongoing6728%
- Status unknown3715%
- Met its primary endpoint177%
- Stopped: other or unclear135%
- Missed its primary endpoint62%
- Stopped: funding21%
- Stopped: safety1<1%
- Stopped: enrollment or feasibility1<1%
- Stopped: sponsor or business decision1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA